erlotinib hydrochloride has been researched along with aspirin in 6 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (aspirin) | Trials (aspirin) | Recent Studies (post-2010) (aspirin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 48,947 | 6,817 | 13,778 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | aspirin (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.35 | |
| Integrin beta-3 | Homo sapiens (human) | 5 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.8252 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 1.375 | |
| Integrin alpha-IIb | Homo sapiens (human) | 5 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.271 | |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | 2.4 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 2.15 | |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 0.3 | |
| 4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | 2.4 | |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.35 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4081 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Hanayama, K; Hirashima, T; Imamura, F; Kanazawa, S; Kinoshita, Y; Nomura, S; Sasada, S; Siomi, K; Tujimoto, M; Yamaguchi, K | 1 |
| Heinonen, T; Huttala, O; Mannerström, M; Sabell, E; Sarkanen, JR; Toimela, T; Ylikomi, T | 1 |
| Kassie, F; Song, JM; Upadhyaya, P | 1 |
| López-Contreras, F; López-Muñoz, R; Martin-Martin, A; Molina-Berríos, A; Muñoz-Uribe, M; Pérez-Laines, J; Rivera-Dictter, A | 1 |
| Burke, CA; Chick, RC; Cindass, JL; Clifton, GT; Ensley, DC; Hale, DF; Hickerson, AT; Kemp Bohan, PM; Mankaney, G; Peoples, GE; Sohn, V; Vreeland, TJ | 1 |
1 review(s) available for erlotinib hydrochloride and aspirin
| Article | Year |
|---|---|
Chemoprevention in familial adenomatous polyposis: past, present and future.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Ascorbic Acid; Aspirin; Capsules; Celecoxib; Chemoprevention; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Eflornithine; Erlotinib Hydrochloride; Fatty Acids, Nonesterified; Genes, APC; Humans; Sirolimus; Sulindac; TOR Serine-Threonine Kinases; Vitamins | 2021 |
5 other study(ies) available for erlotinib hydrochloride and aspirin
| Article | Year |
|---|---|
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Quinazolines; Thromboxane B2; Treatment Outcome | 2009 |
Intra-laboratory validated human cell-based in vitro vasculogenesis/angiogenesis test with serum-free medium.
Topics: 2-Methoxyestradiol; Adipose Tissue; Aspirin; Cells, Cultured; Culture Media; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Estradiol; Human Umbilical Vein Endothelial Cells; Humans; Laboratories; Levamisole; Mannitol; Methimazole; Neovascularization, Physiologic; Reproducibility of Results; Serum; Stromal Cells; Teratogens; Toxicity Tests; Umbilical Cord; Vascular Endothelial Growth Factor A | 2017 |
Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway.
Topics: A549 Cells; Animals; Aspirin; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Nitric Oxide; Protein Kinase Inhibitors; Signal Transduction | 2018 |
Reconsidering the Role of Cyclooxygenase Inhibition in the Chemotherapeutic Value of NO-Releasing Aspirins for Lung Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Nitric Oxide; Nitro Compounds | 2019 |